• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

预测慢性血栓栓塞性肺动脉高压患者长期生存的列线图的开发与验证

Development and Validation of a Nomogram for Predicting the Long-Term Survival in Patients With Chronic Thromboembolic Pulmonary Hypertension.

作者信息

Hu Song, Tan Jiang-Shan, Liu Sheng, Guo Ting-Ting, Song Wu, Peng Fu-Hua, Wu Yan, Gao Xin, Hua Lu

机构信息

Thrombosis Center, Key Laboratory of Pulmonary Vascular Medicine, National Clinical Research Center of Cardiovascular Diseases, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Department of Cardiac Surgery, Adult Cardiac Surgery Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

出版信息

Am J Cardiol. 2022 Jan 15;163:109-116. doi: 10.1016/j.amjcard.2021.09.045. Epub 2021 Nov 10.

DOI:10.1016/j.amjcard.2021.09.045
PMID:34774286
Abstract

There remains a lack of prognosis models for patients with chronic thromboembolic pulmonary hypertension (CTEPH). This study aims to develop a nomogram predicting 3-, 5-, and 7-year survival in patients with CTEPH and verify the prognostic model. Patients with CTEPH diagnosed in Fuwai Hospital were enrolled consecutively between May 2013 and May 2019. Among them, 70% were randomly split into a training set and the other 30% as a validation set for external validation. Cox proportional hazards model was used to identify the potential survival-related factors which were candidate variables for the establishment of nomogram and the final model was internally validated by the bootstrap method. A total of 350 patients were included in the final analysis and the median follow-up period of the whole cohort was 51.2 months. Multivariate analysis of Cox proportional hazards regression showed body mass index, mean right atrial pressure, N-terminal pro-brain natriuretic peptide (per 500 ng/ml increase in concentration), presence of anemia, and main treatment choice were the independent risk factors of mortality. The nomogram demonstrated good discrimination with the corrected C-index of 0.82 in the training set, and the C-index of 0.80 (95% CI: 0.70 to 0.91) in the external validation set. The calibration plots also showed a good agreement between predicted and actual survival in both training and validation sets. In conclusion, we developed an easy-to-use nomogram with good apparent performance using 5 readily available variables, which may help physicians to identify CTEPH patients at high risk for poor prognosis and implement medical interventions.

摘要

慢性血栓栓塞性肺动脉高压(CTEPH)患者仍然缺乏预后模型。本研究旨在开发一种列线图,预测CTEPH患者3年、5年和7年生存率,并验证该预后模型。2013年5月至2019年5月期间,连续纳入在阜外医院诊断为CTEPH的患者。其中,70%被随机分为训练集,另外30%作为外部验证的验证集。采用Cox比例风险模型识别潜在的生存相关因素,这些因素是建立列线图的候选变量,最终模型通过自举法进行内部验证。最终分析共纳入350例患者,整个队列的中位随访时间为51.2个月。Cox比例风险回归多因素分析显示,体重指数、平均右心房压力、N末端脑钠肽前体(浓度每增加500 ng/ml)、贫血的存在以及主要治疗选择是死亡的独立危险因素。该列线图在训练集中校正C指数为0.82,具有良好的区分度,在外部验证集中C指数为0.80(95%CI:0.70至0.91)。校准图还显示,训练集和验证集中预测生存与实际生存之间具有良好的一致性。总之,我们使用5个易于获得的变量开发了一种易于使用且具有良好表观性能的列线图,这可能有助于医生识别预后不良的高危CTEPH患者并实施医疗干预。

相似文献

1
Development and Validation of a Nomogram for Predicting the Long-Term Survival in Patients With Chronic Thromboembolic Pulmonary Hypertension.预测慢性血栓栓塞性肺动脉高压患者长期生存的列线图的开发与验证
Am J Cardiol. 2022 Jan 15;163:109-116. doi: 10.1016/j.amjcard.2021.09.045. Epub 2021 Nov 10.
2
Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?波生坦或马昔腾坦治疗慢性血栓栓塞性肺动脉高压?
Lung. 2019 Dec;197(6):753-760. doi: 10.1007/s00408-019-00274-9. Epub 2019 Oct 3.
3
Chronic thromboembolic pulmonary hypertension.慢性血栓栓塞性肺动脉高压。
Lancet Respir Med. 2014 Jul;2(7):573-82. doi: 10.1016/S2213-2600(14)70089-X. Epub 2014 Jun 2.
4
Advances in targeted therapy for chronic thromboembolic pulmonary hypertension.靶向治疗慢性血栓栓塞性肺动脉高压的进展。
Heart Fail Rev. 2019 Nov;24(6):949-965. doi: 10.1007/s10741-019-09798-x.
5
Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.真实世界中使用塞乐西帕作为附加疗法联合口服药物治疗肺动脉高压或慢性血栓栓塞性肺动脉高压患者的经验:一项回顾性分析。
Lung. 2019 Jun;197(3):353-360. doi: 10.1007/s00408-019-00222-7. Epub 2019 Apr 8.
6
Evolving spectrum of treatment for CTEPH.CTEPH 的治疗演变。
Curr Opin Pulm Med. 2020 Sep;26(5):406-413. doi: 10.1097/MCP.0000000000000696.
7
MR-proADM Predicts Exercise Capacity and Survival Superior to Other Biomarkers in PH.MR-proADM 预测运动能力和生存率优于 PH 的其他生物标志物。
Lung. 2015 Dec;193(6):901-10. doi: 10.1007/s00408-015-9802-y. Epub 2015 Sep 12.
8
Long-term outcomes of surgery for chronic thromboembolic pulmonary hypertension compared with medical therapy at a single Korean center.韩国一家中心慢性血栓栓塞性肺动脉高压手术与药物治疗的长期疗效比较
Korean J Intern Med. 2017 Sep;32(5):855-864. doi: 10.3904/kjim.2016.049. Epub 2016 Oct 13.
9
Chronic thromboembolic pulmonary hypertension: the evolving treatment landscape.慢性血栓栓塞性肺动脉高压:不断演变的治疗格局
Eur Respir Rev. 2015 Jun;24(136):173-7. doi: 10.1183/16000617.00001515.
10
Balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension.球囊肺血管成形术治疗无法手术的慢性血栓栓塞性肺动脉高压患者。
Heart. 2013 Oct;99(19):1415-20. doi: 10.1136/heartjnl-2012-303549. Epub 2013 Jul 11.

引用本文的文献

1
Chronic Thromboembolic Pulmonary Hypertension in Females: Clinical Features and Survival.女性慢性血栓栓塞性肺动脉高压:临床特征与生存情况
J Cardiovasc Dev Dis. 2022 Sep 16;9(9):308. doi: 10.3390/jcdd9090308.
2
COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study.COVID-19 与肺动脉高压患者:一项全国性前瞻性队列研究。
Am J Respir Crit Care Med. 2022 Sep 1;206(5):573-583. doi: 10.1164/rccm.202112-2761OC.